Staphylococcal bacteraemia, fusidic acid, and jaundice

Area of Science:

• * Infectious Diseases
• * Pharmacology
• * Hepatology

Background:

• * Staphylococcal bacteraemia is a serious infection requiring effective antimicrobial treatment.
• * Fusidic acid is a key antibiotic for treating staphylococcal infections.
• * Liver function abnormalities, including jaundice, are potential adverse effects of antibiotic therapy.

Purpose of the Study:

• * To investigate the incidence and characteristics of jaundice associated with fusidic acid treatment in patients with staphylococcal bacteraemia.
• * To compare the risk of jaundice between fusidic acid and other antimicrobial agents.
• * To assess the impact of intravenous versus oral administration of fusidic acid on jaundice development.

Main Methods:

• * Retrospective analysis of 250 patients with staphylococcal bacteraemia treated over 10 years.
• * Comparison of jaundice incidence in patients receiving fusidic acid (n=131) versus other antimicrobials (n=119).
• * Analysis of jaundice development based on route of administration (intravenous vs. oral) and pre-existing liver function.

Main Results:

• * Jaundice developed in 34% of patients receiving fusidic acid compared to 2% on other antimicrobials.
• * Intravenous fusidic acid was associated with a significantly higher incidence of jaundice (48%) than oral administration (13%).
• * Jaundice typically appeared within 48 hours of intravenous fusidic acid initiation and resolved upon drug discontinuation in surviving patients.

Conclusions:

• * Fusidic acid, particularly the intravenous formulation, is associated with a significant risk of jaundice in patients with staphylococcal bacteraemia.
• * Caution is advised when prescribing fusidic acid to patients with abnormal liver function.
• * Transitioning to oral fusidic acid as soon as clinically feasible is recommended for patients receiving intravenous therapy.